lenalidomide has been researched along with etoposide in 20 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (etoposide) | Trials (etoposide) | Recent Studies (post-2010) (etoposide) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 18,306 | 3,693 | 4,900 |
| Protein | Taxonomy | lenalidomide (IC50) | etoposide (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | 1.153 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 1.4284 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.187 | |
| Caspase-3 | Homo sapiens (human) | 1 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.4299 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D | 1 |
| Mateos, MV; San-Miguel, JF | 1 |
| Berthou, C; Eveillard, JR; Guillerm, G; Ianotto, JC; Tempescul, A | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Beaven, AW; Bejot, C; Bhattacharyya, P; Carini, C; Chow, KF; Donato, ML; Feldman, T; Gadaleta, G; Goy, A; Kdiry, S; Mato, AR; Pecora, AL; Protomastro, EA; Rowley, SD; Smith, J; Stives, S; Timberg, M; Valentinetti, M; Yang, X; Yannotti, KM | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A | 1 |
| Amrein, PC; Attar, EC; Avigan, D; Ballen, KK; Brunner, AM; DeAngelo, DJ; Ebert, BL; Fathi, AT; Hobbs, GS; Luptakova, K; McMasters, M; Rosenblatt, J; Sperling, AS; Steensma, DP; Stone, RM; Stroopinsky, D; Wadleigh, M; Washington, A; Werner, L | 1 |
| Bishop, MR; Cohen, KS; Godfrey, JK; Karmali, R; Karrison, T; Kline, JP; Nabhan, C; Rapoport, AP; Smith, SM; Stadler, WM; Venugopal, P | 1 |
| Ballen, K; Bhatt, S; Brunner, A; Burgess, M; Carr, SA; DeAngelo, DJ; Ebert, BL; Fell, G; Garcia, JS; Keshishian, H; Letai, A; Medeiros, BC; Neuberg, D; Sperling, AS; Stone, RM; Yilma, B | 1 |
| Au-Yeung, R; Chan, TSY; Ip, AHW; Kwong, YL; Pang, AWK | 1 |
| Chen, M; Chen, W; Jiang, Q; Li, T; Liu, Y; Peng, J; Shi, X; Wu, J; Xi, X; Yu, X; Zhang, S; Zhu, Y | 1 |
| Anderson, KC; Badros, A; Beksac, M; Bladé, J; Caers, J; Cavo, M; Dimopoulos, MA; Dispenzieri, A; Einsele, H; Engelhardt, M; Fernández de Larrea, C; Gahrton, G; Gay, F; Hájek, R; Hungria, V; Jurczyszyn, A; Kröger, N; Kyle, RA; Leal da Costa, F; Leleu, X; Lentzsch, S; Mateos, MV; Merlini, G; Mohty, M; Moreau, P; Rasche, L; Reece, D; Richardson, PG; Rosiñol, L; Sezer, O; Sonneveld, P; Usmani, SZ; Van de Donk, NWCJ; Vanderkerken, K; Vesole, DH; Waage, A; Zamagni, E; Zweegman, S | 1 |
| Beaupre, D; Chhabra, S; de Vos, S; Huang, DW; Kimball, AS; Kwei, K; Neuenburg, JK; Phillips, T; Ping, J; Popplewell, L; Staudt, LM; Wilson, WH; Wright, G | 1 |
| Iida, S; Inagaki, H; Ishida, T; Ito, A; Iwasaki, H; Kusumoto, S; Masaki, A; Murase, T; Muto, R; Nakano, N; Sakamoto, Y; Takeshita, M; Tashiro, Y; Tokunaga, M; Ueda, R; Utsunomiya, A; Yonekura, K | 1 |
| Dong, T; Jing, F; Song, W; Wang, L; Wang, Y; Xiao, S; Xue, H | 1 |
3 review(s) available for lenalidomide and etoposide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Disease Management; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasmacytoma; Prognosis; Transplantation, Autologous | 2021 |
6 trial(s) available for lenalidomide and etoposide
| Article | Year |
|---|---|
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult | 2016 |
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis | 2018 |
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Translocation, Genetic; Treatment Outcome; Vincristine | 2019 |
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Etoposide; Female; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondria; Mitoxantrone | 2020 |
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prednisone; Treatment Outcome; Vincristine | 2021 |
11 other study(ies) available for lenalidomide and etoposide
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Combined Modality Therapy; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Ifosfamide; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Failure; Vincristine | 2009 |
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Prednisone; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2011 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Herpesvirus 4, Human; Humans; Lenalidomide; Lymphoma, T-Cell; Male; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisolone; Vincristine | 2020 |
Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report.
Topics: Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Examination; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Lenalidomide; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Skin Neoplasms; Transplantation, Autologous; Vincristine | 2020 |
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; CD28 Antigens; Cyclophosphamide; DNA Copy Number Variations; Doxorubicin; Etoposide; Female; Genes, p53; Hematopoietic Stem Cell Transplantation; Humans; INDEL Mutation; Kaplan-Meier Estimate; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mutation; Nitrosourea Compounds; Polymorphism, Single Nucleotide; Prednisolone; Prednisone; Prognosis; Receptors, CCR4; Vincristine; Vindesine | 2021 |
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Frail Elderly; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisone; Retrospective Studies; Rituximab | 2022 |